% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Leichsenring:120471,
      author       = {J. Leichsenring and A.-L. Volckmar and N. Magios and C. M.
                      Morais de Oliveira$^*$ and R. Penzel and R. Brandt and M.
                      Kirchner$^*$ and F. Bozorgmehr and M. Thomas$^*$ and P.
                      Schirmacher$^*$ and A. Warth and V. Endris and A.
                      Stenzinger$^*$},
      title        = {{S}ynonymous {EGFR} variant p.{Q}787{Q} is neither
                      prognostic nor predictive in patients with lung
                      adenocarcinoma.},
      journal      = {Genes, chromosomes $\&$ cancer},
      volume       = {56},
      number       = {3},
      issn         = {1045-2257},
      address      = {New York, NY},
      publisher    = {Wiley-Liss},
      reportid     = {DKFZ-2017-00900},
      pages        = {214 - 220},
      year         = {2017},
      abstract     = {Patients with non-small cell lung cancer (NSCLC) harboring
                      activating mutations in the Epidermal Growth Factor Receptor
                      (EGFR) benefit from targeted therapies. A synonymous
                      polymorphism (rs1050171, p.Q787Q) was shown to be associated
                      with improved overall survival (OS) in colorectal cancer
                      patients. As data in NSCLC are limited, we retrospectively
                      analyzed associations of p.Q787Q with clinicopathological
                      parameters including clinical response and outcome in
                      patients with lung adenocarcinoma (ADC) who received
                      tyrosine kinase inhibitor (TKI) therapy. Of 642 ADC patients
                      whose tumors were profiled by next generation sequencing,
                      102 $(15.9\%)$ carried EGFR mutations targetable by TKIs
                      $(30.4\%$ male patients, median age 65.1 y, $19.6\%$ smokers
                      with 12.8 median pack years). Seventy-nine patients
                      $(77.5\%)$ received TKI therapy either as a first- or
                      second-line therapy. Of the 102 EGFR-mutant tumors, 72
                      $(70.6\%)$ exhibited the p.Q787Q polymorphism and another 12
                      $(11.8\%)$ cases with p.Q787Q harbored an additional TKI
                      insensitive mutation (p.T790M). The polymorphism was neither
                      associated with classic clinicopathological parameters nor
                      with overall survival (21.1 months vs. 20.1 months;
                      P-value = 0.91) or clinical response
                      (P-value = 0.122). The patients with p.T790M had worse
                      survival compared to EGFR activating mutation carriers with
                      and without p.Q787Q when analyzed as a separate group (27.5
                      months, P-value = 0.02). In conclusion, p.Q787Q is
                      neither a suitable prognostic nor predictive biomarker for
                      ADC patients receiving anti-EGFR therapy in first- or
                      second-line of therapy. © 2016 Wiley Periodicals, Inc.},
      cin          = {L101 / G035 / G825 / G835},
      ddc          = {570},
      cid          = {I:(DE-He78)L101-20160331 / I:(DE-He78)G035-20160331 /
                      I:(DE-He78)G825-20160331 / I:(DE-He78)G835-20160331},
      pnm          = {319H - Addenda (POF3-319H)},
      pid          = {G:(DE-HGF)POF3-319H},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:27750395},
      doi          = {10.1002/gcc.22427},
      url          = {https://inrepo02.dkfz.de/record/120471},
}